CARPETS: A Phase I Open Label Study of the Safety and Immune effects of an Escalating Dose of Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T Cells in Patients with Metastatic BRAF-Mutant and GD2-Positive Melanoma

点击翻译按钮获取中文摘要

Malignant melanoma is increasing in incidence in Australia. Current drugs for advanced melanoma are only sometimes effective. BRAF blocking drugs with promising anti-melanoma activity are being tested in Australia but drug resistance is developing. We will genetically engineer the patient’s own T cells to redirect them against the melanoma. The feasibility, safety, and immune effects of this approach will be tested in patients whose advanced melanoma is no longer responding to BRAF blockers.